CMCarl McDonald

Carl McDonald

*This is an algorithmically generated author record based on publicly available information.

Carl McDonald has a total of 153 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    From contamination to fever: The role of endotoxin levels in bacterially contaminated platelet concentrates

    by Marcel Prax, Lea Debes, Paul Adomeit, Michel‐Andrés García‐Otálora, Carl P. McDonald, Marc Cloutier, Ute Gravemann, Opeyemi Adesina, Morenike Adeoye‐Isijola, Josephine Hubloher, et al.

    Background and Objectives: Growth of gram‐negative bacteria in a platelet concentrate (PC) is inevitably accompanied by the accumulation of endotoxin, which is the major component of the outer cell membrane of these organisms. However, less is known about the kinetics of endotoxin accumulation in PC and its biological activity. Therefore, the endotoxin level of Klebsiella pneumoniae contaminated PCs was measured over time. In addition, the biological activity of the contaminants was analysed by an assay that mimics the human fever response in vitro. Materials and Methods: The bacterial endotoxin test and the monocyte activation test were established for PC samples for endotoxin and pyrogen detection, respectively. Low‐count spiking of PCs using K. pneumoniae PEI‐B‐P‐08 was performed by six laboratories, and samples were taken over time. The samples were analysed for the number of viable cells, the amount of endotoxin and their capacity to induce the production of fever‐inducing cytokine interleukin 6 (IL‐6). Results: K. pneumoniae showed fast proliferation in contaminated PCs reaching stationary phase 36 h post‐spiking. Endotoxin was measurable in samples with a bacterial load of more than 10 3 CFU/mL and increased proportionally to the number of bacteria present. IL‐6 production was found to be linked to endotoxin levels in PCs reaching levels of high pyrogenicity 24 h post‐spiking. Conclusion: PCs contaminated with more than 10 3 CFU/mL of K. pneumoniae might be a risk for patients due to their ability to induce pyrogenic reactions during transfusion.

  • Open Access

    Mapping syphilis surveillance: Insights into blood donation screening practices worldwide

    by Michel‐Andrés García‐Otálora, Guillermo Orjuela‐Falla, Carl P. McDonald, Sandra Ramirez‐Arcos, Isbt Transfusion‐Transmitted Infectious Diseases Working Party Subgroup On Bacteria

    Background and Objectives: Syphilis is caused by the bacterial spirochete Treponema pallidum and can be transmitted through blood transfusion. However, there have been less than 10 documented transfusion‐transmitted cases since World War II. Global data comparing population‐level syphilis trends with blood donor reactivity and screening practices are limited. This study aimed to compare syphilis screening practices worldwide and to explore the value of universal donor screening. Materials and Methods: A cross‐sectional international survey was conducted among blood transfusion professionals. Participants reported data collected between 2018 and 2024 on syphilis prevalence, blood donor screening algorithms and reactivity rates, deferral policies and blood safety interventions. Descriptive analyses were performed by year and geographic region. Results: Thirty‐nine participants from 26 countries across five continents answered the survey. Universal donor screening was reported by 35 of 36 institutions providing policy data, with treponemal assays representing the predominant screening approach. Substantial variation was observed in confirmatory testing, donor deferral criteria and donor re‐entry policies. Reactivity rates varied markedly across centres and were higher among first‐time donors compared to repeat donors. Institutions with higher syphilis rates generally reported higher donor reactivity. Routine leukoreduction was reported by 66.7% of institutions, while pathogen reduction technologies were routinely used by 36.1%. Most centres apply indefinite donor deferral and have not considered removing screening. Conclusion: Syphilis screening and donor management practices vary across blood services worldwide despite widespread implementation of universal screening. Local epidemiology, testing strategies and donor eligibility policies contribute to observed differences in donor reactivity and surveillance practices.

  • A congress report of the new Emerging Pathogens and Parasitology Subgroup within the ISBT Working Party on Transfusion‐Transmitted Infectious Diseases

    by Steven J. Drews, Silvano Wendel, Brian Custer, Michael P. Busch, Sandra Ramirez‐Arcos, Carl McDonald, Daniel Candotti, Helen M. Faddy, Benjamin Rader, Jeremy W. Jacobs, et al.

    In 2025, the Parasitology Subgroup of the International Society of Blood Transfusion (ISBT) Transfusion‐Transmitted Infectious Diseases (TTID) Working Party (WP) transitioned into the Emerging Pathogens and Parasitology (EPP) Subgroup (referred to here as the EPP). This followed recognition that the parasitology subgroup's relevance was limited in scope given the small number of transfusion‐transmissible parasites that still lacked effective mitigation. The EPP was proposed to address themes that are not adequately covered by existent subgroups of the TTID WP. In addition to maintaining a focus on transfusion‐transmissible parasitic infections, a major objective of the EPP is horizon scanning for emerging pathogens. Horizon scanning refers to a systematic and proactive approach of information gathering and evaluation to identify early—and often subtle—signals of possible threats, which in this case pertain to blood safety. The EPP will characterize those risks to guide decision making and preparedness, pertaining to the safety and sufficiency of the blood supply. We describe the scope, structure and functioning of the EPP, within the broader TTID WP. We include examples of projects that may be pursued and outputs from horizon scanning a contemporary emerging pathogen. This collectively highlights the strategic relevance and objectives of the EPP.


  • Open Access

    Platelet component safety in the era of new advancements in bacterial screening and pathogen reduction: A congress report of the 2024 ISBT Transfusion‐Transmitted Infectious Diseases Working Party, Bacteria Subgroup

    by Michel‐Andrés García‐Otálora, Carl McDonald, Jennifer Bearne, Bethany Brown, Anthea Cheng, Catherine Humbrecht, Pierre Tiberghien, Sandra Ramirez‐Arcos, For The Isbt Transfusion‐Transmitted Infectious Diseases Working Party Subgroup On Bacteria

    Background and Objectives: High‐income countries have successfully enhanced platelet component (PC) safety with the implementation of mitigation strategies including donor screening, skin disinfection, first aliquot diversion and PC bacterial screening or treatment with pathogen reduction technologies (PRT). This review discusses the experiences of several institutions with the adoption of bacterial screening methods and/or PRT and highlights residual safety risks.Materials and Methods: Data from the American Red Cross (ARC), Australian Red Cross Lifeblood (Lifeblood), Canadian Blood Services (CBS), the Établissement Français du Sang (EFS) and National Health Service Blood and Transplant (NHSBT) were presented at the International Society of Blood Transfusion (ISBT) Congress, Transfusion‐Transmitted Infectious Diseases meeting (Barcelona, June 2024) and were summarised in this report.Results: PC screening with the automated BACT/ALERT culture system began in 2004 in the ARC and CBS, while the system was adopted in 2008 and 2011 by Lifeblood and NHSBT, respectively. Implementation of PC treatment with the PRT INTERCEPT started in 2016, 2022, and 2006 in the ARC, CBS, and EFS, correspondingly.Conclusions: PC screening and PC treatment with PRT have significantly increased product safety. However, there are still residual safety risks posed by challenging organisms such as sporulated Bacillus spp. and toxin‐producing Staphylococcus aureus.


  • Open Access

    Characterization of transfusion‐relevant bacteria reference strains in a lyophilized format

    by Marcel Prax, Carl P. McDonald, Isabelle Bekeredjian‐Ding, Marc Cloutier, Ute Gravemann, Anna Grothaus, Oleg Krut, Xoliswa Mpumlwana, Niamh O'FLaherty, Masahiro Satake, et al.

    Background and Objectives: Blood safety measures used by blood establishments to increase blood component safety can be validated using Transfusion‐Relevant Bacterial Reference Strains (TRBRS). Ultra‐cold storage conditions and manual preparation of the current TRBRS may restrict their practical use. To address this issue, the ISBT Transfusion‐Transmitted Infectious Diseases Working Party's Bacterial Subgroup organized an international study to validate TRBRS in a user‐friendly, lyophilised format.Materials and Methods: Two bacterial strains Klebsiella pneumoniae PEI‐B‐P‐08 and Staphylococcus aureus PEI‐B‐P‐63 were manufactured as lyophilised material. The lyophilised bacteria were distributed to 11 different labs worldwide to assess the robustness for enumeration, identification and determination of growth kinetics in platelet concentrates (PCs).Results: Production of lyophilised TRBRS had no impact on the growth properties compared with the traditional format. The new format allows a direct low‐quantity spiking of approximately 30 bacteria in PCs for transfusion‐relevant experiments. In addition, the lyophilised bacteria exhibit long‐term stability across a broad temperature range and can even be directly rehydrated in PCs without losing viability. Interlaboratory comparative study demonstrated the robustness of the new format as 100% of spiked PC exhibited growth.Conclusion: Lyophilised TRBRS provide a user‐friendly material for transfusion‐related studies. TRBRS in the new format have improved features that may lead to a more frequent use in the quality control of transfusion‐related safety measures in the future.


  • Open Access

    Proliferation of psychrotrophic bacteria in cold‐stored platelet concentrates

    by Sandra Ramirez‐Arcos, Dilini Kumaran, Andrew Cap, Kristin Michelle Cardenas, Marc Cloutier, Justin Ferdin, Ute Gravemann, Patrick Ketter, Patricia Landry, Thea Lu, et al.

    Background and Objectives: Platelet concentrates (PC) are stored at 20–24°C to maintain platelet functionality, which may promote growth of contaminant bacteria. Alternatively, cold storage of PC limits bacterial growth; however, data related to proliferation of psychotrophic species in cold‐stored PC (CSP) are scarce, which is addressed in this study.Materials and Methods: Eight laboratories participated in this study with a pool/split approach. Two split PC units were spiked with ~25 colony forming units (CFU)/PC of Staphylococcus aureus, Klebsiella pneumoniae, Serratia liquefaciens, Pseudomonas fluorescens and Listeria monocytogenes. One unit was stored under agitation at 20–24°C/7 days while the second was stored at 1–6°C/no agitation for 21 days. PC were sampled periodically to determine bacterial loads. Five laboratories repeated the study with PC inoculated with lyophilized inocula (~30 CFU/mL) of S. aureus and K. pneumoniae.Results: All species proliferated in PC stored at 20–24°C, reaching concentrations of ≤109 CFU/mL by day 7. Psychrotrophic P. fluorescens and S. liquefaciens proliferated in CSP to ~106 CFU/mL and ~105 CFU/mL on days 10 and 17 of storage, respectively, followed by L. monocytogenes, which reached ~102 CFU/mL on day 21. S. aureus and K. pneumoniae did not grow in CSP.Conclusion: Psychrotrophic bacteria, which are relatively rare contaminants in PC, proliferated in CSP, with P. fluorescens reaching clinically significant levels (≥105 CFU/mL) before day 14 of storage. Cold storage reduces bacterial risk of PC to levels comparable with RBC units. Safety of CSP could be further improved by implementing bacterial detection systems or pathogen reduction technologies if storage is beyond 10 days.


  • Open Access

    Microbiological environmental contamination in the blood supply chain: An international survey by the bacterial subgroup of the ISBT Transfusion‐Transmitted Infectious Diseases Working Party

    by Sandra Ramirez‐Arcos, Michel Garcia‐Otalora, Carl McDonald, Subgroup On Bacteria Isbt Transfusion‐Transmitted Infectious Diseases Working Party

    Background and Objectives: Blood transfusion centres ensure the quality and safety of transfusable blood components. However, septic transfusion reactions involving environmental contaminants occur. An international survey issued by the ISBT Transfusion‐Transmitted Infectious Diseases Working Party (ISBT‐TTID‐WP) Bacterial Subgroup aimed to collect information regarding microbiological environmental monitoring from transfusion services.Materials and Methods: A Form survey (English and Spanish) with 35 questions was sent to ISBT‐TTID‐WP members. The survey had four sections: (1) respondent personal information, (2) cleaning/disinfection practices during blood component manufacturing, (3) cleaning/disinfection practices during blood component storage and (4) blood component storage bag integrity. Respondents completed the survey electronically, and data were comparatively analysed using Microsoft Excel.Results: There were 49 responses from 20 countries. Five of 49 sites manufacture blood components in a cleanroom, and most use personal protective equipment, although the type varied between sites. Approximately 40% of sites perform environmental monitoring during blood component production, with seven sites providing details about frequency and methods. Most (~94%) centres have procedures for cleaning/disinfection of processing and storage facilities with varying responses regarding areas, frequency and methods. Inconsistency was reported regarding the orientation of platelet component incubation (portrait vs. landscape). Over 93% of sites assess storage bag integrity and report damage to manufacturers, and 49% of centres report septic transfusion reactions potentially linked to damaged storage containers.Conclusion: Data from this survey highlight the need for consensual guidelines for transfusion services regarding cleaning and disinfection practices. Environmental monitoring could be adopted to minimize the risk of blood component contamination for transfusion patient safety.


  • Open Access

    Proof of concept for detection of staphylococcal enterotoxins in platelet concentrates as a novel safety mitigation strategy

    by Sylvia Ighem Chi, Basit Yousuf, Carina Paredes, Jennifer Bearne, Carl McDonald, Sandra Ramirez‐Arcos

    Background and Objectives: Staphylococcus aureus is a predominant contaminant of platelet concentrates (PCs) that can evade detection during screening with culture methods. Importantly, S. aureus produces staphylococcal enterotoxins (SEs) during PC storage, which are linked to slow growth and enhanced biofilm formation. This study investigated timing of SE production during PC storage and feasibility of SE detection as a PC safety strategy.Materials and Methods: Genomic and transcriptomic data of transfusion‐relevant S. aureus PS/BAC/169/17/W, PS/BAC/317/16/W, CI/BAC/25/13/W and CBS2016‐05 were used to determine the presence and differential expression of exotoxin genes in PCs. Trypticase soy broth (TSB) and PCs were inoculated with 1.0E+06 cfu/mL of S. aureus PS/BAC/169/17/W and CBS2016‐05. Expression of SEs at different growth phases was confirmed with Western blotting. PCs were inoculated with 30 cfu/unit of the same strains, and SE detection during PC storage was optimized with a sandwich dot‐ELISA assay.Results: S. aureus genomes contain multiple exotoxin genes including those encoding for SEs. Transcriptome data revealed significant upregulation (0.5–6.7‐fold, p < 0.05) of SE genes in PCs versus TSB. Western blots demonstrated SE production at all growth phases. Notably, dot‐ELISA detected clinically relevant concentrations of SEs (~0.2 μg/mL) at 32 h of PC storage when S. aureus PS/BAC/169/17/W and CBS2016‐05 counts were 1.8E+04 and 1.4E+04 cfu/mL, respectively.Conclusion: Genomic analyses revealed that staphylococcal exotoxins are widely distributed and highly conserved among transfusion‐relevant S. aureus isolates. Furthermore, SEs are significantly upregulated in PCs and detected at 30 h of PC storage. Therefore, bacterial toxin detection could supplement mitigation strategies to enhance PC safety.


  • Open Access

    The international experience of bacterial screen testing of platelet components with automated microbial detection systems: An update

    by Hany Kamel, Sandra Ramirez‐Arcos, Carl McDonald, Isbt Transfusion‐Transmitted Infectious Disease Bacterial Working Party Bacterial Subgroup

    In 2014, the bacterial subgroup of the Transfusion‐Transmitted Infectious Diseases working party of ISBT published a review on the International Experience of Bacterial Screen Testing of Platelet Components (PCs) with an Automated Microbial Detection System. The purpose of this review, which is focused on publications on or after 2014, is to summarize recent experiences related to bacterial contamination of PCs and the use of an automated culture method to safeguard the blood supply. We first reviewed septic transfusion reactions after PC transfusion as reported in national haemovigilance systems along with a few reports from various countries on bacterial contamination of blood products. Next, we reviewed PC automated culture protocols employed by national blood services in the United Kingdom, Australia, Canada and large blood collection organization and hospital transfusion services in the United States. Then, we acknowledged the limitations of currently available culture methodologies in abating the risks of transfusion‐transmitted bacterial infection, through a review of case reports. This review was neither meant to be critical of the literature reviewed nor meant to identify or recommend a best practice. We concluded that significant risk reduction can be achieved by one or a combination of more than one strategy. No one approach is feasible for all institutions worldwide. In selecting strategies, institutions should consider the possible impact on platelet components availability and entertain a risk‐based decision‐making approach that accounts for operational, logistical and financial factors.


  • Assessing the inactivation capabilities of two commercially available platelet component pathogen inactivation systems: effectiveness at end of shelf life

    by Carl P. McDonald, Jennifer Bearne, Kate Aplin, Danuta Sawicka

    Background and objectives: The inactivation capabilities of the two current commercially available pathogen inactivation (PI) systems for platelet components (PC), Mirasol and Intercept, were investigated by determination of the absence of viable bacteria at the end of shelf life by testing the entire contents of the PC by enrichment culture (terminal sterility).Methods: A pool‐and‐split method was used, with two treated units and one untreated control per inoculum concentration. Pairs of PC bags were inoculated with a single bacterial species. Three concentrations (n = 2 per concentration), which incremented tenfold, were tested initially based on published data from the manufacturer. Dependent on these results, the concentrations subsequently tested were either increased or decreased until the inactivation capability of the system was derived. Bacterial count was determined post‐spiking, immediately prior to treatment (2 h from spiking), immediately after treatment and at the end of shelf life (day seven). Enrichment culture was performed immediately prior to treatment, after treatment and at the end of shelf life.Results: The inactivation capabilities, in CFU/ml, of Intercept and Mirasol, respectively, at the end of PC shelf life were as follows: Staphylococcus aureus ≥ 107, 1; Staphylococcus epidermidis ≥106, 2; Klebsiella pneumoniae 105, 1; Streptococcus bovis ≥107, 101, Escherichia coli ≥106, 1; Streptococcus pneumoniae ≥106, 103; Streptococcus mitis ≥107, 101; Listeria monocytogenes ≥107, 101; Streptococcus dysgalactiae ≥107, 1; Serratia marcescens 103, 1; Pseudomonas aeruginosa 103, Mirasol not tested; and Bacillus cereus < 102, Mirasol not tested.Conclusion: The inactivation capability of Intercept was greater than that of Mirasol. Inactivation capability (by terminal sterility) is the most meaningful measure to evaluate a PI system for bacteria, rather than logarithmic reduction assessed immediately after treatment by plate count. PI offers a possible alternative to bacterial screening if treatment is performed at an appropriate time dependent on the inactivation capabilities of the system.